MAD2 in the Spotlight as a Cancer Therapy Regulator
Bargiela-Iparraguirre, J.1,2, Fernandez-Fuente, M, Calés C1, Herrera, L.A2 and Sanchez- Perez, I1,2*
Affiliation
- 1Departament de Bioquímica, Facultad Medicina, Instituto de Investigaciones Biomédicas Madrid CSIC-UAM; Madrid, Spain
- 2Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología (INCan)-Instituto de Investigaciones Biomédicas (IIB), Universidad Nacional Autónoma de México (UNAM), México; Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Circuito Escolar S/N, Ciudad Universitaria, Coyoacán, México
Corresponding Author
Isabel Sanchez-Perez, PhD, Departament de Bioquímica, Facultad Medicina, Instituto de Investigaciones Biomédicas Madrid CSIC-UAM; C/Arturo Duperier 4, 28029 Madrid, Spain, Tel: (+34) 91-5854380/ Fax: (+34) 91- 58544001, E-mail: misanchez@iib.uam.es ; is.perez@uam.es
Citation
Sanchez- Perez, I., et al. MAD2 in the Spotlight as a Cancer Therapy Regulator. (2016) Int J Cancer Oncol 3(2): 1-6.
Copy rights
© 2016 Sanchez- Perez, I. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
MAD2 is a key protein required for mitotic checkpoint function and for the maintenance of accuracy on the mitotic process of every cell cycle. Deregulation of MAD2 is associated with both progression and poor prognosis in cancer disease. However, new evidence highlights the implication of MAD2 in other biological functions besides its classical Mitotic checkpoint implication, such as apoptosis, senescence and also DNA damage repair, which can ultimately define the response to a specific treatment. Development of novel therapeutic approaches and optimization of the existing therapies are now required for the design of successful treatments of cancer. MAD2 is emerging as a new key target for the design of more effective and personalized treatments in cancer disease.
